Société Tunisienne des Maladies Respiratoires et d'Allergologie STMRA - Opinion | Tocilizumab in COVID-19 therapy: who benefits, and how? – the researchers suggest that maybe IL-6 inhibitors should be given only to patients with high IL-6.

Sté Tunisienne des Maladies Respiratoires et d'Allergologie

Cercle des Bureaux - Appartement B 5-3 . 1082 Centre urbain Nord Tunis

Opinion | Tocilizumab in COVID-19 therapy: who benefits, and how? – the researchers suggest that maybe IL-6 inhibitors should be given only to patients with high IL-6.

Zouhair Souissi

Bibliographie

23 juillet 2021

Soyez le premier à commenter!

Tocilizumab in COVID-19 therapy: who benefits, and how? – The Lancet Related: A living WHO guideline on drugs for covid-19 – interleukin-6 receptor blockers are now recommended for patients with severe or critical covid-19. AND M-A: Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 – “The 4% absolute risk reduction […]

The post Opinion | Tocilizumab in COVID-19 therapy: who benefits, and how? – the researchers suggest that maybe IL-6 inhibitors should be given only to patients with high IL-6. appeared first on Links Medicus.

Lu 671 fois